NO20052347L - Forbindelser for behandling av tobakkavhengighet og roykeslutt - Google Patents
Forbindelser for behandling av tobakkavhengighet og roykesluttInfo
- Publication number
- NO20052347L NO20052347L NO20052347A NO20052347A NO20052347L NO 20052347 L NO20052347 L NO 20052347L NO 20052347 A NO20052347 A NO 20052347A NO 20052347 A NO20052347 A NO 20052347A NO 20052347 L NO20052347 L NO 20052347L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- smoking cessation
- addiction treatment
- tobacco addiction
- adenosine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 241000208125 Nicotiana Species 0.000 title abstract 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 title abstract 2
- 206010012335 Dependence Diseases 0.000 title 1
- 230000005586 smoking cessation Effects 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 229960003624 creatine Drugs 0.000 abstract 1
- 239000006046 creatine Substances 0.000 abstract 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Det beskrives fremgangsmåter for behandling eller undertrykkelse av tobakk eller nikotinbruk eller avhengighet, som omfatter administrering av en terapeutisk effektiv mengde av en cytosin-holdig eller cytidin-holdig forbindelse, kreatin-holdig forbindelse, adenosin-holdig eller adenosin-hevende forbindelse til et pattedyr.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42497202P | 2002-11-08 | 2002-11-08 | |
PCT/US2003/035532 WO2004043229A2 (en) | 2002-11-08 | 2003-11-06 | Compounds for the treatment of tobacco dependence and withdrawal |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20052347L true NO20052347L (no) | 2005-06-06 |
NO333979B1 NO333979B1 (no) | 2013-11-04 |
Family
ID=32312907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052347A NO333979B1 (no) | 2002-11-08 | 2005-05-12 | Anvendelse av CDP-kolin for fremstilling av et medikament for behandling av tobakk- eller nikotinavhengighet |
Country Status (15)
Country | Link |
---|---|
US (2) | US7053064B2 (no) |
EP (1) | EP1565055B1 (no) |
JP (1) | JP4667041B2 (no) |
CN (1) | CN100430066C (no) |
AU (1) | AU2003291368A1 (no) |
BR (1) | BR0316054A (no) |
CA (1) | CA2503286C (no) |
ES (1) | ES2427347T3 (no) |
HK (1) | HK1083732A1 (no) |
MX (1) | MXPA05004866A (no) |
NO (1) | NO333979B1 (no) |
PT (1) | PT1565055E (no) |
RU (1) | RU2329811C2 (no) |
UA (1) | UA83011C2 (no) |
WO (1) | WO2004043229A2 (no) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2425114T3 (es) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
CA2542023A1 (en) * | 2003-10-08 | 2005-09-22 | The Mclean Hospital Corporation | Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
US20050113449A1 (en) * | 2003-10-08 | 2005-05-26 | Renshaw Perry F. | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
EP1765364A4 (en) * | 2004-06-10 | 2010-09-22 | Mclean Hospital Corp | PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER |
WO2005122767A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
EP1784199A4 (en) * | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION |
US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
CN102920019B (zh) * | 2012-11-16 | 2014-04-16 | 湖南中烟工业有限责任公司 | 一种具有减害作用的卷烟滤棒添加剂的应用方法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4048316A (en) | 1974-03-04 | 1977-09-13 | Penn Nathar W | Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning |
US4115576A (en) | 1974-04-02 | 1978-09-19 | Penn Nathar W | Compositions and method of employing the same for inhibiting alcohol intoxication |
US4027017A (en) | 1974-07-16 | 1977-05-31 | Chugai Seiyaku Kabushiki Kaisha | Method of treating alcoholism |
EP0120328B1 (en) | 1983-03-01 | 1988-10-19 | C.R.C. Compagnia di Ricerca Chimica S.p.A. | Pharmaceutical compositions containing the cytidine monophosphate of 5-acetamido-3,5-dideoxy-d-glycero-d-galactononulosaminic acid |
DE3400276A1 (de) | 1984-01-05 | 1985-07-18 | Ferrer Internacional S.A., Barcelona | Verwendung von cdp-cholin zur behandlung von neurologischen stoerungen |
EP0188647B1 (en) | 1985-01-24 | 1989-05-24 | NEOPHARMED S.p.A. | Acylated derivatives of cytidine-diphosphate-choline, process for their preparation and their therapeutic use |
IT1201474B (it) | 1985-10-01 | 1989-02-02 | Vincenzo Zappia | Derivati macromolecolarizzati di cdp-colina,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
JPS63202854A (ja) | 1987-02-17 | 1988-08-22 | Sumitomo Electric Ind Ltd | リチウム固体電解質電池 |
ATE93236T1 (de) * | 1987-10-28 | 1993-09-15 | Pro Neuron Inc | Acylatiertes uridin und cytidin und deren verwendungen. |
US5691320A (en) | 1987-10-28 | 1997-11-25 | Pro-Neuron, Inc. | Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis |
US5179126A (en) | 1988-10-26 | 1993-01-12 | Massachusettes Institute Of Technology | Compositions for treating tobacco withdrawl symtoms and methods for their use |
US4999382A (en) | 1988-10-26 | 1991-03-12 | Massachusetts Institute Of Technology | Compositions for treating tobacco withdrawal symptoms and methods for their use |
PT100525B (pt) * | 1991-05-29 | 1999-10-29 | Abbott Lab | Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem |
US5278176A (en) | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
US5472958A (en) * | 1994-08-29 | 1995-12-05 | Abbott Laboratories | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function |
JPH08183737A (ja) | 1994-12-28 | 1996-07-16 | Advance Co Ltd | アルコール吸収抑制剤 |
US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
GB9623859D0 (en) | 1996-11-15 | 1997-01-08 | Chiroscience Ltd | Novel compounds |
US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
US5977174A (en) | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
US6153653A (en) | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
WO2000006174A1 (en) * | 1998-07-31 | 2000-02-10 | Massachusetts Institute Of Technology | Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases |
ES2425114T3 (es) | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
ES2170649B1 (es) | 2000-03-29 | 2003-06-16 | Ferrer Int | Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica. |
US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
US20030114415A1 (en) | 2001-12-14 | 2003-06-19 | Wurtman Richard J. | Compositions and methods for treating and preventing memory impairment using citicoline |
WO2003082211A2 (en) * | 2002-03-27 | 2003-10-09 | The Regents Of The University Of California | Synergy of dopamine d2 and adenosine a2 receptors activates pka signaling via beta/gamma dimers |
BR0317586A (pt) | 2002-12-20 | 2005-11-22 | Mclean Hospital Corp | Compostos para normalização do ciclo sono/vigìlia |
-
2003
- 2003-11-06 EP EP03768760.5A patent/EP1565055B1/en not_active Expired - Lifetime
- 2003-11-06 MX MXPA05004866A patent/MXPA05004866A/es active IP Right Grant
- 2003-11-06 US US10/703,695 patent/US7053064B2/en not_active Expired - Lifetime
- 2003-11-06 BR BR0316054-8A patent/BR0316054A/pt not_active Application Discontinuation
- 2003-11-06 PT PT37687605T patent/PT1565055E/pt unknown
- 2003-11-06 UA UAA200504725A patent/UA83011C2/ru unknown
- 2003-11-06 CN CNB2003801085134A patent/CN100430066C/zh not_active Expired - Fee Related
- 2003-11-06 JP JP2004551866A patent/JP4667041B2/ja not_active Expired - Fee Related
- 2003-11-06 CA CA2503286A patent/CA2503286C/en not_active Expired - Fee Related
- 2003-11-06 WO PCT/US2003/035532 patent/WO2004043229A2/en active Application Filing
- 2003-11-06 AU AU2003291368A patent/AU2003291368A1/en not_active Abandoned
- 2003-11-06 ES ES03768760T patent/ES2427347T3/es not_active Expired - Lifetime
- 2003-11-06 RU RU2005117631/14A patent/RU2329811C2/ru not_active IP Right Cessation
-
2005
- 2005-05-12 NO NO20052347A patent/NO333979B1/no not_active IP Right Cessation
-
2006
- 2006-02-22 HK HK06102369.3A patent/HK1083732A1/xx not_active IP Right Cessation
- 2006-05-25 US US11/440,488 patent/US7601701B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7601701B2 (en) | 2009-10-13 |
PT1565055E (pt) | 2013-09-16 |
AU2003291368A1 (en) | 2004-06-03 |
NO333979B1 (no) | 2013-11-04 |
AU2003291368A8 (en) | 2004-06-03 |
WO2004043229A2 (en) | 2004-05-27 |
JP2006508129A (ja) | 2006-03-09 |
EP1565055A2 (en) | 2005-08-24 |
US20040167093A1 (en) | 2004-08-26 |
RU2005117631A (ru) | 2006-01-20 |
ES2427347T3 (es) | 2013-10-30 |
US20060217344A1 (en) | 2006-09-28 |
CN100430066C (zh) | 2008-11-05 |
CA2503286A1 (en) | 2004-05-27 |
WO2004043229A3 (en) | 2004-08-26 |
EP1565055B1 (en) | 2013-06-12 |
UA83011C2 (ru) | 2008-06-10 |
CA2503286C (en) | 2011-08-30 |
MXPA05004866A (es) | 2005-11-04 |
US7053064B2 (en) | 2006-05-30 |
EP1565055A4 (en) | 2010-12-29 |
HK1083732A1 (en) | 2006-07-14 |
RU2329811C2 (ru) | 2008-07-27 |
JP4667041B2 (ja) | 2011-04-06 |
CN1735343A (zh) | 2006-02-15 |
BR0316054A (pt) | 2005-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052347L (no) | Forbindelser for behandling av tobakkavhengighet og roykeslutt | |
CY1122134T1 (el) | Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας | |
NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
NO20061092L (no) | Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte | |
NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
HK1070251A1 (en) | Method and composition for mentholation of cigarettes | |
MY169308A (en) | Treatment of tnf? related disorders | |
NO20052595L (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
ECSP055867A (es) | Derivados de pirrolopirimidina | |
NO20090469L (no) | Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav | |
EA200870091A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для снятия боли | |
EA200970542A1 (ru) | ИНГИБИТОРЫ ДЕЙСТВИЯ Akt | |
EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
EA200901492A1 (ru) | Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов (sarm) | |
EA200700851A1 (ru) | Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения | |
NO20052348L (no) | Behandling av hemoragisk sjokk | |
DE50310516D1 (de) | Fredericamycin-derivate | |
NO20053111L (no) | Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering. | |
DK1664016T3 (da) | Terapeutiske midler, der er anvendelige til behandling af smerter | |
HUP0300048A2 (hu) | Transzdermális vagy transzmukozális dohányzásról leszoktató készítmények, melyek nikotintartalmú hatóanyagkombinációt tartalmaznak és alkalmazásuk | |
EA199800139A1 (ru) | Способ лечения аденомы толстой кишки | |
EA200200765A1 (ru) | Способ уменьшения или прекращения курения | |
DE60329326D1 (de) | Tace inhibitoren | |
DK1575383T3 (da) | Fugtig snustobaksammensætning, der omfatter mindst ét fortykningsmiddel, og en fremgangsmåde til fremstilling deraf | |
ATE502637T1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |